EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: EFFICACY, SAFETY AND RENAL FUNCTION OUTCOME FROM THE TRANSFORM STUDY

被引：0
|
作者：
Sommerer, C. [1 ]
Arns, W. [1 ]
Weithofer, P. [1 ]
Lehner, F. [1 ]
Banas, B. [1 ]
van der Giet, M. [1 ]
Habicht, A. [1 ]
Renders, L. [1 ]
Rath, T. [1 ]
Bartels, M. [1 ]
Pratschke, J. [1 ]
Hessel, K. [2 ]
Bernhardt, P. [3 ]
Witzke, O. [1 ]
机构：
[1] TRANSFORM Study Grp, Heidelberg, Germany
[2] Novartis Pharma GmbH, Nurnberg, Germany
[3] Novartis Pharma GmbH, Basel, Switzerland
来源：
TRANSPLANT INTERNATIONAL | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
PV04
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [31] LONGER-TERM EFFICACY AND SAFETY OF EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Watarai, Yoshihiko
    Uchida, Kazuharu
    Takahara, Shiro
    Yoshimura, Norio
    Teraoka, Satoshi
    Cornu-Artis, Catherine
    Kobayashi, Eiji
    Takahashi, Kota
    TRANSPLANT INTERNATIONAL, 2013, 26 : 81 - 81
  • [32] Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
    Berger, Stefan P.
    Sommerer, Claudia
    Witzke, Oliver
    Tedesco, Helio
    Chadban, Steve
    Mulgaonkar, Shamkant
    Qazi, Yasir
    de Fijter, Johan W.
    Oppenheimer, Federico
    Cruzado, Josep M.
    Watarai, Yoshihiko
    Massari, Pablo
    Legendre, Christophe
    Citterio, Franco
    Henry, Mitchell
    Srinivas, Titte R.
    Vincenti, Flavio
    Gutierrez, Maria Pilar Hernandez
    Marti, Ana Maria
    Bernhardt, Peter
    Pascual, Julio
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (11) : 3018 - 3034
  • [33] Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study
    Sommerer, Claudia
    Legendre, Christophe
    Citterio, Franco
    Watarai, Yoshihiko
    Oberbauer, Rainer
    Basic-Jukic, Nikolina
    Han, Jackie
    Gawai, Apurva
    Bernhardt, Peter
    Chadban, Steve
    TRANSPLANTATION, 2023, 107 (07) : 1593 - 1604
  • [34] Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study.
    Oberbauer, R.
    Vincenti, F.
    Viklicky, O.
    Huynh-Do, U.
    Kim, D.
    Cruzado, J. M.
    Qazi, Y.
    Kim, M. S.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Kuypers, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 558 - 558
  • [35] TRANSFORM STUDY: IMPACT OF DONOR TYPE ON 12-MONTH OUTCOMES OF EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS
    Berger, Stefan
    Sommerer, Claudia
    Bakr, Ma
    Kim, Myoung Soo
    Danguilan, Romina
    De Fijter, Johan
    Henry, Mitchell
    Luo, Wen-Lin
    Bernhardt, Peter
    Legendre, Christophe
    TRANSPLANT INTERNATIONAL, 2017, 30 : 162 - 163
  • [36] Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study
    Watarai, Yoshihiko
    Danguilan, Romina
    Casasola, Concesa
    Chang, Shen-Shin
    Ruangkanchanasetr, Prajej
    Kee, Terence
    Wong, Hin Seng
    Kenmochi, Takashi
    Amante, Angel Joaquin
    Shu, Kuo-Hsiung
    Ingsathit, Atiporn
    Bernhardt, Peter
    Hernandez-Gutierrez, Maria Pilar
    Han, Duck Jong
    Kim, Myoung Soo
    CLINICAL TRANSPLANTATION, 2021, 35 (10)
  • [37] TRANSFORM STUDY: IMPACT OF DONOR TYPE ON 12-MONTH OUTCOMES OF EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS
    Legendre, C.
    Sommerer, C.
    Bakr, M. A.
    Soo, K. M.
    Danguilan, R.
    De Fijter, J.
    Henry, M.
    Luo, W. L.
    Bernhardt, P.
    Berger, S.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 14 - 15
  • [38] TRANSFORM: Everolimus with reduced calcineurin inhibitors vs mycophenolate with standard calcineurin inhibitors in de novo kidney transplant recipients - baseline data according to donor type
    Watarai, Yoshihiko
    Berger, Stefan P.
    TRANSPLANTATION, 2016, 100 (07) : S673 - S674
  • [39] RENAL FUNCTION IN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM TREATED DE NOVO RENAL TRANSPLANT RECIPIENTS AFTER CALCINEURIN INHIBITOR WITHDRAWAL: THE ZEUS STUDY
    Becker, T.
    Arns, W.
    Budde, K.
    Eisenberger, U.
    Fischer, W.
    Kramer, S.
    Reinke, P.
    Sommerer, C.
    Pietruck, F.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 78 - 79
  • [40] THE TRANSFORM STUDY: 24-MONTHS ANALYSIS OF CARDIOMETABOLIC EVENTS IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN
    Sommerer, C.
    Arns, W.
    Weithofer, P.
    Lehner, F.
    Banas, B.
    van der Giet, M.
    Habicht, A.
    Hessel, K.
    Bernhardt, P.
    Witzke, O.
    TRANSPLANT INTERNATIONAL, 2019, 32 : 26 - 27
12345